{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:37:25Z","timestamp":1784824645607,"version":"3.55.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Interleukin (IL)-23 inhibitors are a class of injectable biologics, which include risankizumab, tildrakizumab and guselkumab, used for the treatment of moderate-to-severe psoriasis. This retrospective review sought to determine the value of IL-23 inhibitor intraclass switching among patients with psoriasis after they experienced loss of efficacy to any IL-23 inhibitor. We conducted a retrospective chart review, including 43 patients who underwent any of 6 potential iterations of IL-23 intraclass switching between November 2017 and November 2023. Most commonly, patients switched from guselkumab or tildrakizumab to risankizumab (84%). On average, patients failed 2.3 biologic treatments (SD 1.3) prior to switching. Postswitching, 81% of patients achieved an affected body surface area (BSA) &amp;lt; 1% after 248.8\u2005days (SD 126.5). BSA immediately prior to intraclass switch was 13.1 (SD 8.9) [95% confidence interval (CI) 10.4\u201315.8] and at most recent follow-up was 2.9 (SD 5.2) (95% CI 2.3\u20135.5). This research adds to a growing body of literature demonstrating the potential of IL-23 intraclass switching in the treatment of moderate-to-severe plaque psoriasis.<\/jats:p>","DOI":"10.1093\/ced\/llae305","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T13:19:49Z","timestamp":1722691189000},"page":"137-140","source":"Crossref","is-referenced-by-count":2,"title":["The utility of interleukin-23 intraclass switching in the treatment of plaque psoriasis: a retrospective review of\u00a043\u00a0cases"],"prefix":"10.1093","volume":"50","author":[{"given":"M Grace","family":"Hren","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreekar","family":"Miriyala","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saakshi","family":"Khattri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"2024122223534828200_llae305-B1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024122223534828200_llae305-B2","doi-asserted-by":"crossref","first-page":"15078","DOI":"10.1038\/s41598-022-18790-9","article-title":"Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)","volume":"12","author":"Graier","year":"2022","journal-title":"Sci Rep"},{"key":"2024122223534828200_llae305-B3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bjd.19575","article-title":"Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment","volume":"184","author":"Reddy","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024122223534828200_llae305-B4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/24755303211037308","article-title":"Tildrakizumab inadequate responders switching to an alternative IL-23 inhibitor: a case series","volume":"6","author":"Song","year":"2021","journal-title":"J\u00a0Psoriasis Psoriatic Arthritis"},{"key":"2024122223534828200_llae305-B5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jdin.2023.05.006","article-title":"Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: a multicenter retrospective study of switching within the interleukin-23 inhibitor class","volume":"12","author":"Bagit","year":"2023","journal-title":"JAAD Int"},{"key":"2024122223534828200_llae305-B6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024122223534828200_llae305-B7","doi-asserted-by":"crossref","first-page":"1964420","DOI":"10.1080\/19420862.2021.1964420","article-title":"A non-clinical comparative study of IL-23 antibodies in psoriasis","volume":"13","author":"Zhou","year":"2021","journal-title":"MAbs"},{"key":"2024122223534828200_llae305-B8","article-title":"Differentiation of therapeutic antibodies targeting interleukin (IL)-23","author":"Elloso"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae305\/59712275\/llae305.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/137\/59712275\/llae305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/137\/59712275\/llae305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T23:53:54Z","timestamp":1734911634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/1\/137\/7726805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,3]]},"published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae305","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,3]]}}}